Retained Earnings (Accumulated Deficit) of ELITE PHARMACEUTICALS INC /NV/ from 31 Mar 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly Retained Earnings (Accumulated Deficit) in USD history and change rate from 31 Mar 2011 to 31 Dec 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Retained Earnings (Accumulated Deficit) for the quarter ending 31 Dec 2025 was $94,292,428, a 32% increase year-over-year.
Source SEC data
View on sec.gov
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $94,292,428 +$43,409,235 +32% 31 Dec 2025 10-Q 17 Feb 2026 2026 Q3
Q3 2025 $112,886,234 +$13,923,489 +11% 30 Sep 2025 10-Q 14 Nov 2025 2026 Q2
Q2 2025 $126,588,641 -$10,815,147 -9.3% 30 Jun 2025 10-Q 14 Aug 2025 2026 Q1
Q1 2025 $120,703,926 -$4,314,659 -3.7% 31 Mar 2025 10-Q 17 Feb 2026 2026 Q3
Q4 2024 $137,701,663 -$17,986,529 -15% 31 Dec 2024 10-Q 13 Feb 2025 2025 Q3
Q3 2024 $126,809,723 -$6,388,235 -5.3% 30 Sep 2024 10-Q 14 Nov 2024 2025 Q2
Q2 2024 $115,773,494 +$19,582,595 +14% 30 Jun 2024 10-Q 14 Aug 2024 2025 Q1
Q1 2024 $116,389,267 +$20,108,631 +15% 31 Mar 2024 10-K 30 Jun 2025 2025 FY
Q4 2023 $119,715,134 +$15,553,510 +11% 31 Dec 2023 10-Q 14 Feb 2024 2024 Q3
Q3 2023 $120,421,488 +$17,817,234 +13% 30 Sep 2023 10-Q 14 Nov 2023 2024 Q2
Q2 2023 $135,356,089 +$4,397,772 +3.1% 30 Jun 2023 10-Q 14 Aug 2023 2024 Q1
Q1 2023 $136,497,898 +$3,561,846 +2.5% 31 Mar 2023 10-K 01 Jul 2024 2024 FY
Q4 2022 $135,268,644 +$7,219,837 +5.1% 31 Dec 2022 10-Q 14 Feb 2023 2023 Q3
Q3 2022 $138,238,722 +$6,533,172 +4.5% 30 Sep 2022 10-Q 14 Nov 2022 2023 Q2
Q2 2022 $139,753,861 +$6,815,010 +4.6% 30 Jun 2022 10-Q 15 Aug 2022 2023 Q1
Q1 2022 $140,059,744 +$8,898,245 +6% 31 Mar 2022 10-K 29 Jun 2023 2023 FY
Q4 2021 $142,488,481 +$5,986,885 +4% 31 Dec 2021 10-Q 14 Feb 2022 2022 Q3
Q3 2021 $144,771,894 +$5,715,605 +3.8% 30 Sep 2021 10-Q 15 Nov 2021 2022 Q2
Q2 2021 $146,568,871 +$6,400,190 +4.2% 30 Jun 2021 10-Q 16 Aug 2021 2022 Q1
Q1 2021 $148,957,989 +$5,088,421 +3.3% 31 Mar 2021 10-K 29 Jun 2022 2022 FY
Q4 2020 $148,475,366 +$6,507,412 +4.2% 31 Dec 2020 10-Q 16 Feb 2021 2021 Q3
Q3 2020 $150,487,499 +$2,634,599 +1.7% 30 Sep 2020 10-Q 16 Nov 2020 2021 Q2
Q2 2020 $152,969,061 -$1,442,704 -0.95% 30 Jun 2020 10-Q 14 Aug 2020 2021 Q1
Q1 2020 $154,046,410 -$2,240,351 -1.5% 31 Mar 2020 10-K 14 Jun 2021 2021 FY
Q4 2019 $154,982,778 -$5,840,424 -3.9% 31 Dec 2019 10-Q 10 Feb 2020 2020 Q3
Q3 2019 $153,122,098 -$6,324,062 -4.3% 30 Sep 2019 10-Q 12 Nov 2019 2020 Q2
Q2 2019 $151,526,357 -$7,311,853 -5.1% 30 Jun 2019 10-Q 09 Aug 2019 2020 Q1
Q1 2019 $151,806,059 -$9,279,321 -6.5% 31 Mar 2019 10-K 29 Jun 2020 2020 FY
Q4 2018 $149,142,354 -$9,445,030 -6.8% 31 Dec 2018 10-Q 11 Feb 2019 2019 Q3
Q3 2018 $146,798,036 -$7,590,893 -5.5% 30 Sep 2018 10-Q 09 Nov 2018 2019 Q2
Q2 2018 $144,214,504 -$3,192,178 -2.3% 30 Jun 2018 10-Q 09 Aug 2018 2019 Q1
Q1 2018 $142,526,738 -$3,673,172 -2.6% 31 Mar 2018 10-K 21 Jun 2019 2019 FY
Q4 2017 $139,697,324 -$4,033,952 -3% 31 Dec 2017 10-Q 09 Feb 2018 2018 Q3
Q3 2017 $139,207,143 -$1,874,518 -1.4% 30 Sep 2017 10-Q 09 Nov 2017 2018 Q2
Q2 2017 $141,022,326 +$548,397 +0.39% 30 Jun 2017 10-Q 09 Aug 2017 2018 Q1
Q1 2017 $138,853,566 +$3,811,181 +2.7% 31 Mar 2017 10-K 14 Jun 2018 2018 FY
Q4 2016 $135,663,372 +$15,500,384 +10% 31 Dec 2016 10-Q 09 Feb 2017 2017 Q3
Q3 2016 $137,332,625 +$1,598,168 +1.2% 30 Sep 2016 10-Q 09 Nov 2016 2017 Q2
Q2 2016 $141,570,723 -$4,321,308 -3.1% 30 Jun 2016 10-Q 09 Aug 2016 2017 Q1
Q1 2016 $142,664,747 -$683,012 -0.48% 31 Mar 2016 10-K 14 Jun 2017 2017 FY
Q4 2015 $151,163,756 +$35,848,105 +19% 31 Dec 2015 10-Q 09 Feb 2016 2016 Q3
Q3 2015 $138,930,793 +$69,097,839 +33% 30 Sep 2015 10-Q 30 Dec 2015 2016 Q2
Q2 2015 $137,249,415 +$92,159,041 +40% 30 Jun 2015 10-Q 30 Dec 2015 2016 Q1
Q1 2015 $141,981,735 +$83,024,911 +37% 31 Mar 2015 10-K 15 Jun 2016 2016 FY
Q4 2014 $187,011,861 -$48,802,791 -35% 31 Dec 2014 10-Q 17 Feb 2015 2015 Q3
Q3 2014 $208,028,632 -$70,881,412 -52% 30 Sep 2014 10-Q 14 Nov 2014 2015 Q2
Q2 2014 $229,408,456 -$101,898,747 -80% 30 Jun 2014 10-Q 14 Aug 2014 2015 Q1
Q1 2014 $225,006,646 -$96,575,271 -75% 31 Mar 2014 10-K 15 Jun 2015 2015 FY
Q4 2013 $138,209,070 -$8,180,744 -6.3% 31 Dec 2013 10-Q 14 Feb 2014 2013 Q3
Q3 2013 $137,147,220 +$2,244,269 +1.6% 30 Sep 2013 10-Q 14 Nov 2013 2013 Q2
Q2 2013 $127,509,709 +$12,931,689 +9.2% 30 Jun 2013 10-Q 14 Aug 2013 2013 Q1
Q1 2013 $128,431,375 +$1,487,928 +1.1% 31 Mar 2013 10-K 30 Jun 2014 2014 FY
Q4 2012 $130,028,326 -$7,114,187 -5.8% 31 Dec 2012 10-Q 14 Feb 2013 2012 Q3
Q3 2012 $139,391,489 -$7,716,355 -5.9% 30 Sep 2012 10-Q 14 Nov 2012 2012 Q2
Q2 2012 $140,441,398 +$5,153,057 +3.5% 30 Jun 2012 10-Q 14 Aug 2012 2012 Q1
Q1 2012 $129,919,303 -$15,058,274 -13% 31 Mar 2012 10-K 21 Jun 2013 2012 FY
Q4 2011 $122,914,139 31 Dec 2011 10-Q 14 Feb 2012 2011 Q3
Q3 2011 $131,675,134 30 Sep 2011 10-Q 14 Nov 2011 2011 Q2
Q2 2011 $145,594,455 30 Jun 2011 10-Q/A 19 Aug 2011 2011 Q1
Q1 2011 $114,861,029 31 Mar 2011 10-K 29 Jun 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.